Abstract:
Objective To observe the clinical efficacy and safety of apatinib in the treatment of small-cell lung cancer that has failed multiline therapies.
Methods We analyzed the clinical data of 41 patients with advanced small-cell lung cancer admitted to our hospital from January 2016 to December 2017 who had previously received more than one line of treatment. Patients took apatinib daily until disease progression or adverse reactions become intolerable. We analyzed the disease control rate, progression survival period, and adverse events.
Results Among the 41 patients studied, the objective response rate, disease control rate, and progression-free survival were 12.19%, 80.48%, and 4.1 months, respectively. During the treatment, the common adverse events were grade 1-3 hypertension and hand-foot syndrome. Other common side effects were proteinuria and fatigue, mainly of grade 1-2, often without special treatment. Most adverse reactions could be relieved by reducing the drug dosage.
Conclusions Apatinib therapy can extend the survival period of patients with small-cell lung cancer who are eligible for the therapy. The role of apatinib in the treatment of small-cell lung cancer involving the failure of multiline therapies warrants further discussion in clinical practice.
下载: